The pandemic’s disruption galvanised the biopharma industry into unprecedented action, demonstrating what’s possible when the global scientific community collaborates in exceptional ways an
The single biggest monetary difference that can be made to the successor to the UK’s 2019 Voluntary Scheme for branded medicines pricing and access (VPAS) is to address the question of how
Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma compani
Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market.
A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how these products can find a smoother path to
The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and cost-effectiveness of new treatments.